Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
04:01pm, Tuesday, 05'th Jul 2022
Celldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
08:35am, Tuesday, 05'th Jul 2022 Benzinga
Gainers
Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64.
Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.
Fast Radius, Inc. (NASDAQ: FSRD) jumped 41.2
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
03:49pm, Monday, 04'th Jul 2022 Zacks Investment Research
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
01:12pm, Monday, 04'th Jul 2022
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
04:06pm, Friday, 01'st Jul 2022 Benzinga
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 49.3% to $0.2852. Allena Pharmaceuticals
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
02:05pm, Friday, 01'st Jul 2022 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.
The Dow traded up 0.38% to 30,893.82 while the NASDAQ rose 0.50% to 11,084.33. The S&P also rose, gai
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
10:01pm, Thursday, 30'th Jun 2022 GlobeNewswire Inc.
-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile--Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week 1
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
01:24pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
10:49am, Wednesday, 22'nd Jun 2022
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
Celldex Announces Two New Appointments to its Board of Directors
08:01pm, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
HAMPTON, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company’s Board of Directo
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
08:05pm, Monday, 06'th Jun 2022 GlobeNewswire Inc.
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Heal
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
04:05pm, Monday, 06'th Jun 2022
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Health
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with a
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
08:13am, Wednesday, 11'th May 2022
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
09:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
